(Information sent by the signatory company)
Villoria Ophthalmologists Clinic incorporates Valeda therapy
(Pontevedra, November 29, 2023.-) In Spain, about 700,000 people suffer from low vision due to Macular Degeneration. It is a degenerative disease that affects the macula, the central area of the retina, and is the leading cause of blindness in older people in Spain.
Dry Macular Degeneration represents 80% of cases. In these patients, vision loss is slow and progressive, leading to visual blindness.
“Until now, there was no treatment for dry Macular Degeneration. Luckily, this has now changed. We already have a new light therapy that can treat dry Macular Degeneration and it is expected that two new medications will appear next year,” explains Dr. Daniel Villoria, retina specialist at Clínica Villoria, the only center in Vigo and Pontevedra. where this new procedure is available.
The appearance of this new therapy, known as Valeda, represents a ray of hope for patients with dry Macular Degeneration. It is the first treatment with CE marking from the European Union for dry Macular Degeneration. Previously, no other alternative had managed to improve the vision of these patients.
“Mitochondria dysfunction and oxidative stress are two key factors in the progression of Macular Degeneration.” “Using the Valeda equipment, with low-energy light with 3 specific wavelengths, it is possible to stimulate the retina and improve vision,” says Dr. Villoria.
It is necessary to repeat several light sessions, it is completely painless and does not require surgery. Patients lead a completely normal life after the procedure.
“A very important point is that it does not have risks for ocular health nor does it cause discomfort to the patient,” explains Dr. Villoria.
Clinical trials have shown that Valeda achieves a slight improvement in vision and also appears to protect against the progression of Macular Degeneration.
“The best candidates are patients in the intermediate stages of Macular Degeneration, when they begin to notice vision loss,” explains Dr. Villoria. “In more advanced stages, the death of neurons in the retina occurs, making it impossible to recover vision.”
In France and other European countries it began to be used in 2019. Clínica Villoria Ophthalmologists has been carrying out the Valeda treatment since April 2023, becoming the first and only center in the province, and the second in all of Galicia, where it is available. The commitment to the visual health of patients and their desire to incorporate the latest technology make Villoria Ophthalmologists a reference center throughout Galicia.
Next year, two new medications are expected to arrive in Europe that slow the progression of the most severe forms of dry AMD. They are already approved by the US FDA and approval in Europe is expected in 2024.
Issuer: Villoria Clinic
For more information:
Journalistic Office
Contact email: comunicados@prensaymedios.com
